Last month, the FDA approved Eylea (VEGF-Trap, aflibercept) for the treatment of wet macular degeneration. The new drug does not need to be injected as often as Lucentis, yet it seems that the visual improvement is the same; that is, fewer injections yield similar improvement in vision…for the first year of therapy.
Keep in mind that we are always interested in a drug’s ability to improve vision, and sustain these im (Read more...)